Biosimilar tocilizumab proves to be a cost-effective treatment for rheumatoid arthritis in Spain, enhancing access to ...

Number 5: The FDA has approved Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq), the sixth pair of denosumab biosimilars to receive the green light from the agency. The approvals, granted to ...

Major advancements in biosimilars emerge in Europe and Middle East and North Africa (MENA) region, enhancing patient access ...

Biosimilars and generics drive significant health care savings, yet a concerning lack of biosimilar development for biologics ...

Australia's adoption of etanercept biosimilars enhances access to rheumatoid arthritis treatments, maintaining treatment ...